Roflumilast Reduces COPD Exacerbations in Specific Patient Groups
Author Information
Author(s): Stephen I Rennard, Peter M A Calverley, Udo M Goehring, Dirk Bredenbröker, Fernando J Martinez
Primary Institution: Nebraska Medical Center
Hypothesis
Can a subset of COPD patients benefit more from roflumilast treatment in reducing exacerbations?
Conclusion
Roflumilast significantly reduced exacerbation frequency in COPD patients with chronic bronchitis and those using inhaled corticosteroids.
Supporting Evidence
- Roflumilast decreased exacerbations by 14.3% compared to placebo.
- Patients with chronic bronchitis saw a 26.2% reduction in exacerbations.
- Concurrent use of inhaled corticosteroids led to an 18.8% reduction in exacerbations.
Takeaway
Roflumilast helps some people with lung problems called COPD feel better by reducing their flare-ups, especially if they have chronic bronchitis.
Methodology
Post-hoc pooled analysis of two randomized, double-blind, placebo-controlled studies.
Potential Biases
Potential biases due to the post-hoc analysis and the nature of the patient selection.
Limitations
The post-hoc nature of the analysis may limit the conclusions and is primarily hypothesis-generating.
Participant Demographics
Predominantly male patients with severe-to-very-severe COPD.
Statistical Information
P-Value
0.026
Statistical Significance
p = 0.026
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website